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The article describes the synthetic peptide IRL 1038 as 
having a much higher affinity to ETB receptors (Ki = 6 
11 nM) than to ET, receptors (Ki = 4OC700 nM) in 
various tissue membranes. It was also shown that this 
peptide antagonized the ET,-mediated contraction of 
guinea pig ileal and tracheal smooth muscles. Since the 
publication of the data, we have synthesized more than 
20 different batches of IRL 1038, some of which showed 
potencies and selectivities almost equivalent o the pub- 
lished data. However, the other batches, including 
batches synthesized by external suppliers, exhibited sig- 
nificantly higher Ki of 5&400 nM for the binding to ET, 
receptors in porcine lung membranes. 
We have very carefully investigated the physico-chem- 
ical properties of IRL 1038 in aqueous solutions at dif- 
ferent pH (pH 7-10) and peptide concentrations, using 
fluorescence and proton NMR spectroscopy. At high pH 
(pH lo), the peptide does not aggregate and two kinds 
of non-aggregated states were observed by NMR spec- 
troscopy. There was, however, no evident correlation 
between the two non-aggregated states and binding af- 
A note from the Managing Editor 
finity to ET, receptors. On the other hand, at lower pH, 
the NMR and fluorescence data strongly indicate that 
intermolecular association and/or irreversible aggrega- 
tion occur. The state and degree of aggregation also vary 
as a function of peptide concentration and ionic strength. 
The state of aggregation is not consistent in all batches 
investigated. Hence, one possible explanation for the 
variation of the Ki values might be attributed to these 
different molecular states and the degree of aggregation. 
Based on the biological data obtained with the active 
batches, we believe that IRL 1038 has the potential to be 
a good and useful tool for the investigation of ET, recep- 
tor-mediated functions. However, since we have not been 
able to reproducibly synthesize IRL 1038 having the 
claimed potency and selectivity, and no active compound 
is available to further investigate this problem, we regret- 
tably retract the above article. 
We deeply apologize to researchers who have spent 
time and effort attempting to reproduce the data claimed 
in our publication. 
At a time when competition occasionally degenerates in to fierce polemics (into which some authors try to involve 
even the Managing Editors), I am grateful to those authors for whom truth has premium over ill-understood personal 
prestige. 
G. Semenza 
Zurich, 19 February 1994 
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